Precision BioSciences Q3 net loss narrows to $7.6 million on $12.7 million warrant gain
Precision BioSciences reported a third-quarter 2026 net loss of $7.6 million, or $(0.28) per share, compared with a net loss of $21.8 million, or $(1.84) per share, a year earlier. The improvement was driven mainly by a non-cash gain on the warrant liability, while cash, cash equivalents and restricted cash fell to $108.0 million, which the company says supports runway through 2028.
Key points
- Net loss was $7.6 million, or $(0.28) per share, versus $21.8 million, or $(1.84) per share, in the third quarter of 2025; the company attributes the decrease mainly to a $12.7 million gain on the change in fair value of the warrant liabili
- Research and development expenses were $12.7 million, versus $13.4 million a year earlier; general and administrative expenses were $7.7 million, versus $7.3 million
- Cash, cash equivalents and restricted cash were $108.0 million at September 30, 2026, down from $137.2 million at December 31, 2025
- No revenue was reported for the quarter, versus less than $0.1 million a year earlier; PBGENE-HBV late-breaking oral presentation is scheduled for November 8, 2026, with abstract data public November 5
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.